Evidence map›Paper›PMID 38672081›Full record

ArticleBiomedicines2024

Efficacy of Alkaline Phosphatase in Critically Ill Patients with COVID-19: A Multicentre Investigator-Initiated Double-Blind Randomised Placebo-Controlled Trial.

Anouk Pijpe, Stephan G Papendorp, Joost W van der Heijden, Ben Vermin, Iris Ertugrul, Michael W J Ritt, Björn Stessel, Ina Callebaut, Albertus Beishuizen, Marcel Vlig and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Anouk PijpeDepartment of Intensive Care, Red Cross Hospital, Vondellaan 13, 1942 LE Beverwijk, The Netherlands.ORCID 0000-0002-3594-4621
Stephan G PapendorpDepartment of Intensive Care, Red Cross Hospital, Vondellaan 13, 1942 LE Beverwijk, The Netherlands.
Joost W van der HeijdenDepartment of Internal Medicine, Spaarne Gasthuis, Spaarnepoort 1, 2134 TM Hoofddorp, The Netherlands.
Ben VerminDepartment of Intensive Care Medicine, Spaarne Gasthuis, Spaarnepoort 1, 2134 TM Hoofddorp, The Netherlands.
Iris ErtugrulDepartment of Intensive Care Medicine, Spaarne Gasthuis, Spaarnepoort 1, 2134 TM Hoofddorp, The Netherlands.
Michael W J RittDepartment of Intensive Care, Red Cross Hospital, Vondellaan 13, 1942 LE Beverwijk, The Netherlands.
Björn StesselDepartment of Intensive Care Medicine, Jessa Hospital, Stadsomvaart 11, 3500 Hasselt, Belgium.ORCID 0000-0002-1422-2777
Ina CallebautDepartment of Intensive Care Medicine, Jessa Hospital, Stadsomvaart 11, 3500 Hasselt, Belgium.ORCID 0000-0002-6666-6783
Albertus BeishuizenIntensive Care Center, Medisch Spectrum Twente, Koningsplein 1, 7512 KZ Enschede, The Netherlands.
Marcel VligAssociation of Dutch Burn Centres, Zeestraat 27-29, 1941 AJ Beverwijk, The Netherlands.ORCID 0000-0003-3280-5877
Joost JimminkBurn Centre, Red Cross Hospital, Vondellaan 13, 1942 LE Beverwijk, The Netherlands.
Henk J HuijgenDepartment of Clinical Chemistry, Red Cross Hospital, 1942 LE Beverwijk, The Netherlands.
Paul P M van ZuijlenDepartment of Plastic, Reconstructive and Hand Surgery, Amsterdam UMC Location Vrije Universiteit, Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
Esther MiddelkoopDepartment of Plastic, Reconstructive and Hand Surgery, Amsterdam UMC Location Vrije Universiteit, Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
Evelien de JongDepartment of Intensive Care, Red Cross Hospital, Vondellaan 13, 1942 LE Beverwijk, The Netherlands.ORCID 0000-0002-5274-9713
Association of Dutch Burn Centres · NLSpaarne Ziekenhuis · NLJessa Hospital · BEAmsterdam UMC Location University of Amsterdam · NLMedisch Spectrum Twente · NL

Funding

Swaanswijk B.V. 2020.153
6 · The paper itself

Abstract

backgroundEfforts to identify therapies to treat hospitalised patients with COVID-19 are being continued. Alkaline phosphatase (AP) dephosphorylates pro-inflammatory adenosine triphosphate (ATP) into anti-inflammatory adenosine.

methodsIn a randomised controlled trial, we investigated the safety and efficacy of AP in patients with SARS-CoV-2 infection admitted to the ICU. AP or a placebo was administered for four days following admission to the ICU. The primary outcome was the duration of mechanical ventilation. Mortality in 28 days, acute kidney injury, need for reintubation, safety, and inflammatory markers relevant to the described high cytokine release associated with SARS-CoV-2 infection were the secondary outcomes.

resultsBetween December 2020 and March 2022, 97 patients (of the intended 132) were included, of which 51 were randomised to AP. The trial was terminated prematurely based on meeting the threshold for futility. Compared to the placebo, AP did not affect the duration of mechanical ventilation (9.0 days vs. 9.3 days,

conclusionsAlkaline phosphatase (AP) therapy in COVID-19 ICU patients showed no significant benefits in this trial.

Indexed as

alkaline phosphataseCOVID-19inflammatory responsemechanical ventilation

Identifiers

PMID38672081
PMCPMC11048668
OpenAlexW4393140255

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.